...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Metabolism: Clinical and Experimental >The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
【24h】

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

机译：降脂药物的有益作用超出降脂作用：普伐他汀，阿托伐他汀和非诺贝特在IIa型和IIb型高脂血症患者中的比较研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hyperlipidemia is an important risk factor for atherosclerosis. Hemorheological factors contribute to morbidity and mortality in patients with dyslipidemia. We evaluated the effects of 3 antihyperlipidemic drugs (pravastatin, atorvastatin, and fenofibrate), which have different mechanisms of action and different patterns of action on lipid profiles, on erythrocyte deformability and fibrinogen levels in patients with type IIa and type IIb hyperlipidemia. Twenty-one patients ( 4 men and 17 women) with type IIa and IIb hyperlipidemia were randomized to 3 drugs (pravastatin 20 mg/d, atorvastatin 10 mg/d, fenofibrate 250 mg/d) for 8 weeks. Plasma glucose, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) analysis were performed on a BM-Hitachi 747-200 autoanalyzer (Hitachi-Roche, Tokyo, Japan). Fibrinogen analysis was performed according to Clauss method. Erythrocyte deformability was assessed with cell transit analysis device. There was no significant difference in body mass index, lipid profile, fibrinogen level, and erythrocyte deformability index values among the groups before treatment ( P > .05). In all groups, there were statistically significant reductions in total LDL-C levels ( P < .05). The triglyceride levels were significantly reduced in the atorvastatin and fenofibrate groups ( P < .05), but not in the pravastatin group ( P > .05). There was no significant change in HDL-C levels during the treatment with statins ( P > .05), but there was a significant increase in the fenofibrate group ( P < .05). Mean erythrocyte deformability index was improved in all the groups ( P < .05). There was no significant change in fibrinogen levels during the treatment of pravastatin and atorvastatin ( P > .05), but in fenofibrate group, fibrinogen levels were significantly decreased ( P < .05). The 3 groups of antihyperlipidemic drugs have beneficial effects on the erythrocyte deformability index. Only fenofibrate has significant beneficial effects on the fibrinogen levels.
机译：高脂血症是动脉粥样硬化的重要危险因素。血液流变学因素导致血脂异常患者的发病率和死亡率。我们评估了3种抗高血脂药物（普伐他汀，阿托伐他汀和非诺贝特）对IIa型和IIb型高脂血症患者的脂质分布，红细胞变形能力和纤维蛋白原水平具有不同的作用机制和作用方式，其作用不同。 21名IIa型和IIb型高脂血症患者（4名男性和17名女性）被随机分配3种药物（普伐他汀20 mg / d，阿托伐他汀10 mg / d，非诺贝特250 mg / d），持续8周。在BM-Hitachi 747-200自动分析仪（Hitachi-Roche，东京，日本）上进行血浆葡萄糖，总胆固醇，甘油三酸酯，高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）分析。 ）。根据Clauss方法进行纤维蛋白原分析。用细胞转运分析仪评估红细胞的可变形性。治疗前各组之间的体重指数，血脂谱，纤维蛋白原水平和红细胞变形性指数值无显着差异（P> 0.05）。在所有组中，LDL-C总水平均有统计学显着降低（P <.05）。阿托伐他汀和非诺贝特组的甘油三酯水平显着降低（P <.05），普伐他汀组未降低（P> .05）。他汀类药物治疗期间HDL-C水平无显着变化（P> .05），但非诺贝特组显着增加（P <.05）。所有组的平均红细胞变形性指数均得到改善（P <.05）。普伐他汀和阿托伐他汀治疗期间血纤蛋白原水平无明显变化（P> .05），但非诺贝特组的血纤蛋白原水平显着降低（P <.05）。 3组降血脂药对红细胞变形性指数有有益作用。仅非诺贝特对纤维蛋白原水平具有显着的有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号